Novel antibody–drug conjugates for triple negative breast cancer

Aiko Nagayama, Neelima Vidula, Leif Ellisen, Aditya Bardia

Research output: Contribution to journalReview articlepeer-review

74 Citations (Scopus)


Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
Publication statusPublished - 2020


  • antibody–drug conjugates
  • breast cancer
  • triple negative breast cancer

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Novel antibody–drug conjugates for triple negative breast cancer'. Together they form a unique fingerprint.

Cite this